Feb 19, 2020   SOURCE: PR NewsWire

Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae - Pipeline Insight, 2020

DUBLIN, Feb. 19, 2020 /PRNewswire/ -- The "Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae market. A detailed picture of the Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae pipeline landscape is provided, which includes the disease overview and Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae treatment guidelines.

The assessment part of the report embraces in-depth Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae commercial assessment and clinical assessment of the Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Report highlights

    --  A better understanding of disease pathogenesis contributing to the
        development of novel therapeutics for Multi-Drug-Resistant (MDR)
        Neisseria Gonorrhoeae .
    --  In the coming years, the Multi-Drug-Resistant (MDR) Neisseria
        Gonorrhoeae market is set to change due to the rising awareness of the
        disease, and incremental healthcare spending across the world; which
        would expand the size of the market to enable the drug manufacturers to
        penetrate more into the market.
    --  The companies and academics that are working to assess challenges and
        seek opportunities that could influence Multi-Drug-Resistant (MDR)
        Neisseria Gonorrhoeae R&D. The therapies under development are focused
        on novel approaches to treat/improve the disease condition.
    --  A detailed portfolio of major pharma players who are involved in fueling
        the Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae treatment market.
        Several potential therapies for Multi-Drug-Resistant (MDR) Neisseria
        Gonorrhoeae are under investigation. With the expected launch of these
        emerging therapies, it is expected that there will be a significant
        impact on the Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae market
        size in the coming years.
    --  Our in-depth analysis of the pipeline assets (in early-stage, mid-stage
        and late stage of development for the treatment of Multi-Drug-Resistant
        (MDR) Neisseria Gonorrhoeae ) includes therapeutic assessment and
        comparative analysis. This will support the clients in the
        decision-making process regarding their therapeutic portfolio by
        identifying the overall scenario of the research and development
        activities.

Key questions answered in the report

    --  What are the current options for Multi-Drug-Resistant (MDR) Neisseria
        Gonorrhoeae treatment?
    --  How many companies are developing therapies for the treatment of
        Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?
    --  What are the principal therapies developed by these companies in the
        industry?
    --  How many therapies are developed by each company for the treatment of
        Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?
    --  How many Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae emerging
        therapies are in early-stage, mid-stage, and late stage of development
        for the treatment of Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?
    --  Out of total pipeline products, how many therapies are given as a
        monotherapy and in combination with other therapies?
    --  What are the key collaborations (Industry-Industry, Industry-Academia),
        Mergers and acquisitions, and major licensing activities that will
        impact Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae market?
    --  Which are the dormant and discontinued products and the reasons for the
        same?
    --  What is the unmet need for current therapies for the treatment of
        Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?
    --  What are the recent novel therapies, targets, mechanisms of action and
        technologies developed to overcome the limitation of existing
        Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae therapies?
    --  What are the clinical studies going on for Multi-Drug-Resistant (MDR)
        Neisseria Gonorrhoeae and their status?
    --  What are the results of the clinical studies and their safety and
        efficacy?
    --  What are the key designations that have been granted for the emerging
        therapies for Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?
    --  How many patents are granted and pending for the emerging therapies for
        the treatment of Multi-Drug-Resistant (MDR) Neisseria Gonorrhoeae?

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2rtgbw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/multi-drug-resistant-mdr-neisseria-gonorrhoeae---pipeline-insight-2020-301007647.html

SOURCE Research and Markets